U.S. FDA nod for Aurobindo’s Droxidopa capsules

U.S. FDA nod for Aurobindo’s Droxidopa capsules

The Hindu

Drugmaker Aurobindo Pharma has received final approval from the U.S. Food and Drug Administration (US FDA) to manufacture and market Droxidopa capsules, 100 mg, 200 mg and 300 mg. Droxidopa Capsules are generic version of Lundbeck NA’s Northera capsules and will be launched immediately, the company said on Friday. The approved product has an estimated market size of $352 million for the 12 months ending December 2020, a release said quoting IQVIA numbers.
Read full story on The Hindu
Share this story on:-
More Related News
Markets continue to fall for fourth day dragged by auto stocks, foreign fund outflows

Equity indices Sensex and Nifty close lower due to auto stocks, foreign fund outflows, and global market concerns.

Rupee falls 7 paise to close at 86.71 against U.S. dollar

Rupee falls against dollar on Friday due to foreign fund outflows, U.S. dollar index recovery, and weak domestic markets.

Demand for air-conditioners doubles in four years to 15 million units owing to climate-change, comfort

India's HVAC&R industry is booming, with AC market doubling to 15 million units, driven by sustainability and government support.

Flash India PMI expands to 60.6 in February on robust service sector indicators

HSBC reports rapid growth in India's private sector activity, with services leading the way, indicating economic expansion.

Invest Kerala Global Meet: Kerala CM Pinarayi Vijayan promises to cut red tape

Kerala Chief Minister Pinarayi Vijayan highlights investor-friendly initiatives and growth in investment potential at Invest Kerala Global Summit.

Sensex, Nifty decline in early trade on foreign fund outflows, weak U.S. peers

Equity indices decline due to foreign fund outflows, weak US markets, and tariff threats, impacting Sensex and Nifty.

Rupee rises 14 paise to 86.50 against U.S. dollar in early trade

Rupee expected to trade negatively due to weak equities, but cushioned by crude oil prices; influenced by RBI minutes.

S&P upgrades Kotak Mahindra Bank to ‘BBB’ after RBI lifts curbs

S&P Global upgrades Kotak Mahindra Bank's credit rating to 'BBB' after RBI lifts operational curbs, positioning bank for growth.

Sri Lanka not seeking to renegotiate Adani power deal, says top official from Energy Ministry

Adani Green withdraws from Sri Lanka wind farm project amid tariff dispute, government open to future collaboration.

Government extends tenure of CEA Anantha Nageswaran till March 2027

Government extends Chief Economic Adviser V. Anantha Nageswaran's tenure until March 2027, following approval by Appointments Committee of the Cabinet.

Skoda Volkswagen can’t play victim, will have to fall in line on tax demand: Customs to Bombay HC

Skoda Auto Volkswagen India faces $1.4 billion tax demand for allegedly misclassifying imports, customs department warns legal action.

Stock markets fall for 3rd day amid uncertainty over U.S. tariff measures, weak Asian peers

Benchmark indices Sensex and Nifty decline for third day due to tariff threats, weak Asian markets, and foreign fund outflows.

Rupee rises 33 paise to close at 86.65 against U.S. dollar

Rupee strengthens against the dollar, supported by weakening American currency, amid global economic uncertainties and foreign fund outflows.